Table 2 Overall response rate

From: Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

 

ITT population

Evaluable population

 

WHO

RECIST

WHO

RECIST

Number of patients

63

63

60

60

Complete response (CR)

—

—

—

—

Partial response (PR)

5 (7.9%)

6 (9.5%)

5 (8.3%)

6 (10%)

Overall response (CR+PR)

5 (7.9%)

6 (9.5%)

5 (8.3%)

6 (10%)

95% Confidence interval

(2.6–17.6)

(3.6–19.6)

(2.8–18.4)

(3.8–20.5)

Stable disease

31 (49.2%)

31 (49.2%)

30 (50%)

30 (50%)

Disease control (CR+PR+NC)

36 (57.1%)

37 (58.7%)

35 (58.3%)

35 (58.3%)

Disease progression (PD)

25 (39.7%)

24 (38.1%)

25 (41.7%)

24 (40%)

Not evaluable

2 (3.2%)

2 (3.2%)

  
Back to article page